Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL)

Next Previous
Trial Profile

A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MB-105-March-Biosciences (Primary)
  • Indications T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors March Biosciences

Most Recent Events

  • 22 Apr 2025 According to March Biosciences media release, company announced that the first patient has been dosed at The University of Texas MD Anderson Cancer Center in its Phase 2 clinical trial evaluating MB-105.
  • 28 Jan 2025 According to March Biosciences media release, the company recently closed a $28.4 million Series A financing to advance Phase 2 development of MB-105 and strengthen its manufacturing capabilities to support future commercialization.
  • 27 Jan 2025 Planned initiation date changed from 1 Feb 2025 to 30 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top